Journal article 67 views 13 downloads
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe
,
Jan Hillert,
Lars Forsberg,
Anna Glaser,
Ali Manouchehrinia,
Ryan Ramanujam,
Tim Spelman,
Pernilla Klyve,
Jiri Drahota,
Dana Horakova,
Hanna Joensen,
Luigi Pontieri,
Melinda Magyari,
David Ellenberger,
Alexander Stahmann,
Helmut Butzkueven ,
Anneke Van Der Walt ,
Vladimir Bezlyak,
Carol Lines,
Rod Middleton
Therapeutic Advances in Neurological Disorders, Volume: 16
Swansea University Author:
Rod Middleton
-
PDF | Version of Record
© The Author(s), 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License.
Download (1.17MB)
DOI (Published version): 10.1177/17562864231198963
Abstract
Introduction:Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising the approach to diagnosis of disease course, for exa...
| Published in: | Therapeutic Advances in Neurological Disorders |
|---|---|
| ISSN: | 1756-2864 1756-2864 |
| Published: |
SAGE Publications
2023
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa66408 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
Introduction:Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising the approach to diagnosis of disease course, for example, assigning RRMS or secondary progressive MS (SPMS) diagnoses, allows examination of the impact of health system characteristics on the stated clinical diagnosis and treatment access.Methods:We analysed registry data from six cohorts in five countries (Czech Republic, Denmark, Germany, Sweden and United Kingdom) on patients with an initial diagnosis of RRMS. We standardised our approach utilising a pre-existing algorithm (DecisionTree, DT) to determine patient diagnoses of RRMS or secondary progressive MS (SPMS). We identified five global drivers of DMT prescribing: Provision, Availability, Funding, Monitoring and Audit, data were analysed against these concepts using meta-analysis and univariate meta-regression.Results:In 64,235 patients, we found variations in DMT use between countries, with higher usage in RRMS and lower usage in SPMS, with correspondingly lower usage in the UK compared to other registers. Factors such as female gender (p = 0.041), increasing disability via Expanded Disability Status Scale (EDSS) score (p = 0.004), and the presence of monitoring (p = 0.029) in SPMS influenced the likelihood of receiving DMTs. Standardising the diagnosis revealed differences in reclassification rates from clinical RRMS to DT-SPMS, with Sweden having the lowest rate Sweden (Sweden 0.009, range: Denmark 0.103 – UK portal 0.311). Those with higher EDSS at index (p < 0.03) and female gender (p < 0.049) were more likely to be reclassified from RRMS to DT-SPMS. The study also explored the impact of diagnosis on DMT usage in clinical SPMS, finding that the prescribing environment and auditing practices affected access to treatment.Discussion:This highlights the importance of a healthcare system’s approach to verifying the clinical label of MS course in facilitating appropriate prescribing, with some flexibility allowed in uncertain cases to ensure continued access to treatment. |
|---|---|
| Keywords: |
big data; clinical audit; decision tree; disease registers; international collaboration; multiple sclerosis |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
This study was wholly funded by Novartis AG. |